Skip to main content

Table 2 Clinical characteristics after 6 weeks of dapagliflozin and placebo treatment, respectively

From: SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

 

Placebo

Mean ± SD (change from baseline)

p-value vs. baseline

Dapagliflozin

Mean ± SD (change from baseline)

p-value vs. baseline

BMI (kg/m2)

29.9 ± 4.2 (+ 0.1)

0.846

29.5 ± 4.1 (−0.3)

< 0.001

HbA1c (%)

6.79 ± 0.8 (+ 0.12)

0.064

6.62 ± 0.7 (− 0.05)

0.224

Glucose

 Fasting (mg/dl)

135 ± 32 (+ 2.0)

0.325

114 ± 19 (−18)

< 0.001

 Postprandial† (mg/dl)

180 ± 67 (+ 1.0)

0.766

154 ± 46 (− 24)

< 0.001

Office blood pressure

 Systolic (mmHg)

129 ± 13 (− 0.1)

0.340

126 ± 12 (− 4.0)

0.015

 Diastolic (mmHg)

79 ± 8.7 (− 1.0)

0.827

78 ± 8.8 (− 2.0)

0.058

 Heart rate (bpm)

67.8 ± 9.6 (− 1.3)

0.123

68.2 ± 10.6 (− 0.9)

0.332

24-h ambulatory blood pressure

 Systolic (mmHg)

129 ± 10.8 (− 0.5)

0.172

126 ± 10.8 (−3.0)

0.010

 Diastolic (mmHg)

77.1 ± 7.3 (0.0)

0.765

75.4 ± 7.7 (−2.0)

0.024

 Heart rate (bpm)

75.7 ± 9.5 (+ 1.4)

0.997

74.1 ± 7.6 (− 0.8)

0.849

 Haematocrit (%)

40.3 ± 3.1 (+ 0.2)

0.389

41.1 ± 2.9 (+ 1.0)

< 0.001

 Serum sodium conc. (mmol/l)

138.1 ± 1.6 (− 0.5)

0.034

138.3 ± 1.6 (− 0.3)

0.308

 Urinary sodium excretion over 24 h (mmol/day)

222.5 ± 103.6 (− 6.0)

0.660

210.1 ± 71.2 (+ 6.5)

0.586

  1. N = 59. BMI body mass index, HbA1c glycated haemoglobin
  2. †A standardised breakfast was given